首页> 外文期刊>Modern Pathology >Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases
【24h】

Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases

机译:宫颈腺瘤性癌:59例详细分析形态,免疫组化学概况和临床结果

获取原文
       

摘要

Although 2014 World Health Organization criteria require unequivocal glandular and squamous differentiation for a diagnosis of cervical adenosquamous carcinoma, in practice, adenosquamous carcinoma diagnoses are often made in tumors that lack unequivocal squamous and/or glandular differentiation. Considering the ambiguous etiologic, morphological, and clinical features and outcomes associated with adenosquamous carcinomas, we sought to redefine these tumors. We reviewed slides from 59 initially diagnosed adenosquamous carcinomas (including glassy cell carcinoma and related lesions) to confirm an adenosquamous carcinoma diagnosis only in the presence of unequivocal malignant glandular and squamous differentiation. Select cases underwent immunohistochemical profiling as well as human papillomavirus (HPV) testing by in situ hybridization. Of the 59 cases originally classified as adenosquamous carcinomas, 34 retained their adenosquamous carcinoma diagnosis, 9 were reclassified as pure invasive stratified mucin-producing carcinomas, 10 as invasive stratified mucin-producing carcinomas with other components (such as HPV-associated mucinous, usual-type, or adenosquamous carcinomas), and 4 as HPV-associated usual or mucinous adenocarcinomas with benign-appearing squamous metaplasia. Two glassy cell carcinomas were reclassified as poorly differentiated usual-type carcinomas based on morphology and immunophenotype. There were significant immunophenotypic differences between adenosquamous carcinomas and pure invasive stratified mucin-producing carcinomas with regard to HPV (p<0.0001), PAX8 (p=0.038; more in adenosquamous carcinoma), p40 (p<0.0001; more in adenosquamous carcinoma), p63 (p=0.0018; more in adenosquamous carcinoma) and MUC6 (p<0.0001; less in adenosquamous carcinoma), HNF-1beta (p=0.0023), vimentin (p=0.0003), p53 (p=0.0004), and CK7 (p=0.0002) expression. Survival outcomes were similar between all groups. Adenosquamous carcinomas should be diagnosed only in the presence of unequivocal malignant glandular and squamous differentiation. The two putative glassy cell carcinomas studied did not meet our criteria for adenosquamous carcinoma, and categorizing them as such should be reconsidered.
机译:虽然2014年世界卫生组织标准需要令人明确的腺体和鳞状和鳞状分化,用于诊断宫颈腺瘤性癌,在实践中,腺细胞正癌癌诊断通常在缺乏明确鳞状和/或腺体分化的肿瘤中进行。考虑到与腺瘤癌相关的含糊不清的病因,形态和临床特征和结果,我们寻求重新定义这些肿瘤。我们审查了59次初步诊断的腺细胞正癌癌(包括玻璃细胞癌及相关病变)的幻灯片,仅在径向透明腺和鳞状分化的存在下确认腺细胞正癌诊断。选择案件接受免疫组织化学分析以及原位杂交的人乳头瘤病毒(HPV)测试。 59例最初归类为腺细胞正癌癌,34保留其腺细胞正癌癌诊断,9例被重新分类为纯侵入分层粘蛋白的癌,10作为侵入性分层粘蛋白的癌癌,其与其他组分(如HPV相关的粘液,通常 - 类型或腺细胞正癌癌)和4作为HPV相关的通常或粘液腺癌,具有良性出现的鳞状细胞鳞状。基于形态和免疫蛋白型重新分配了两种玻璃细胞癌。关于HPV(P <0.0001),PAX8(P <0.038),P40(P <0.038),P40(P <0.03,腺瘤癌),P40(P <0.03),P40(p <0.01;腺癌癌中的纯侵袭分层粘液产生癌癌存在显着的免疫蛋白质差异。 P63(p = 0.0018;腺瘤正癌更多)和MUC6(P <0.0001;腺癌癌的P <0.0001),HNF-1β(P = 0.0023),Vimentin(P = 0.0003),P53(P = 0.0004)和CK7( p = 0.0002)表达式。所有群体之间的生存结果相似。仅在不确定的恶性腺体和鳞状分化存在下仅诊断腺瘤菌癌。研究的两个推定的玻璃细胞癌没有符合我们对腺细胞癌癌的标准,并将它们分类为应被重新考虑。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号